Sangamo Therapeutics (SGMO) Tops Q4 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. MSFT
4. META
5. PLTR
6. CSCO
7. KTOS
8. LDOS
9. LBRX
10. BMY

Go back to Sangamo Therapeutics (SGMO) Tops Q4 EPS by 8c

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

February 24, 2022 4:01 PM EST

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported fourth quarter and full year 2021 financial results and recent business highlights.

In 2021, we continued to advance the development of genomic medicines for patients across multiple therapeutic areas using our innovative technologies, said Sandy Macrae, Chief Executive Officer of Sangamo. We along with our partners presented compelling clinical data in our three lead programs and advanced development of preclinical product candidates using our second-generation... More